We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+8.56%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$14.8B
AUM Growth
+$1.79B
(+14%)
Cap. Flow
+$849M
Cap. Flow
% of AUM
5.76%
Top 10 Holdings %
Top 10 Hldgs %
16.89%
Holding
1,178
New
178
Increased
473
Reduced
324
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$128M |
| 2 |
Intel
INTC
|
+$88.4M |
| 3 |
Prudential Financial
PRU
|
+$72.7M |
| 4 |
Lam Research
LRCX
|
+$62.6M |
| 5 |
SBA Communications
SBAC
|
+$58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$98.3M |
| 2 |
Target
TGT
|
+$86.8M |
| 3 |
Occidental Petroleum
OXY
|
+$74.7M |
| 4 |
Synchrony
SYF
|
+$61.6M |
| 5 |
Intercontinental Exchange
ICE
|
+$57.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.69% |
| 2 | Healthcare | 13.54% |
| 3 | Financials | 13.08% |
| 4 | Consumer Discretionary | 12.97% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
826
Foster
FSTR
$443M
| $624K | ﹤0.01% |
33,475
-2,199
| -6% | -$38.6K |
|
827
Old Second Bancorp
OSBC
$1.24B
| $608K | ﹤0.01% |
49,067
+30,468
| +164% | +$408K |
|
|
AYX
828
DELISTED
Alteryx Inc
AYX
| $605K | ﹤0.01% |
7,028
| – | – |
|
829
Adaptive Biotechnologies
ADPT
$3.56B
| $604K | ﹤0.01% |
14,773
+4,435
| +43% | +$172K |
|
830
Allegro MicroSystems
ALGM
$8.58B
| $604K | ﹤0.01% |
+21,799
| New | +$569K |
|
831
Denali Therapeutics
DNLI
$3.67B
| $602K | ﹤0.01% |
7,679
-37,617
| -83% | -$2.33M |
|
832
GSI Technology
GSIT
$216M
| $600K | ﹤0.01% |
106,715
-18,278
| -15% | -$113K |
|
833
OceanFirst Financial
OCFC
$1.7B
| $598K | ﹤0.01% |
+28,676
| New | +$642K |
|
|
OPI
834
DELISTED
Office Properties Income Trust
OPI
| $595K | ﹤0.01% |
+20,311
| New | +$582K |
|
835
Global Net Lease
GNL
$1.87B
| $587K | ﹤0.01% |
31,744
-1,015
| -3% | -$19.3K |
|
836
Solid Biosciences
SLDB
$771M
| $584K | ﹤0.01% |
10,631
| – | – |
|
837
HNI Corp
HNI
$3B
| $578K | ﹤0.01% |
13,141
-113,320
| -90% | -$4.91M |
|
838
Amtech Systems
ASYS
$278M
| $576K | ﹤0.01% |
59,775
-476
| -0.8% | -$4.88K |
|
|
STSA
839
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $576K | ﹤0.01% |
81,742
-92,654
| -53% | -$500K |
|
|
CDAK
840
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
| $575K | ﹤0.01% |
31,056
-84,803
| -73% | -$1.63M |
|
841
WEC Energy
WEC
$37.7B
| $566K | ﹤0.01% |
6,359
-44,760
| -88% | -$4.22M |
|
842
Hope Bancorp
HOPE
$1.72B
| $563K | ﹤0.01% |
39,703
-835
| -2% | -$12.7K |
|
|
LJPC
843
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $562K | ﹤0.01% |
131,300
-123
| -0.1% | -$527 |
|
844
Northwest Bancshares
NWBI
$2.25B
| $559K | ﹤0.01% |
41,004
-1,314
| -3% | -$18.5K |
|
845
Fossil Group
FOSL
$239M
| $556K | ﹤0.01% |
38,929
-4,465
| -10% | -$58.8K |
|
846
Vaalco Energy
EGY
$594M
| $554K | ﹤0.01% |
170,511
-95,735
| -36% | -$263K |
|
847
Information Services Group
III
$185M
| $554K | ﹤0.01% |
94,776
| – | – |
|
848
Ironwood Pharmaceuticals
IRWD
$611M
| $541K | ﹤0.01% |
42,036
-238,508
| -85% | -$2.73M |
|
849
1st Source
SRCE
$2.07B
| $532K | ﹤0.01% |
11,453
-276
| -2% | -$13.2K |
|
850
Inspire Medical Systems
INSP
$1.42B
| $529K | ﹤0.01% |
2,735
-19,228
| -88% | -$3.81M |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2021 Portfolio in Review
As of Q2 2021, Jacobs Levy Equity Management held 1,178 positions worth $14.8B, up 14% from $13B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Jacobs Levy Equity Management deployed $849M of net new capital in Q2 2021, opening 178 new positions and adding to 473 existing holdings. Its largest new stake was Lam Research: 991,120 shares worth $64.5M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 22% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Qualcomm, an estimated $98.3M trimmed.
- Jacobs Levy Equity Management's largest Q2 2021 buy was Lam Research: 991,120 shares worth $64.5M.
- Jacobs Levy Equity Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $128M increase.
- Jacobs Levy Equity Management's biggest Q2 2021 reduction was Qualcomm, cutting an estimated $98.3M.
- Jacobs Levy Equity Management fully exited Occidental Petroleum in Q2 2021, selling an estimated $74.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 17% of its $14.8B portfolio in Q2 2021.
- Jacobs Levy Equity Management opened 178 new positions and closed 161 in Q2 2021.
- Jacobs Levy Equity Management's portfolio value rose 14% quarter-over-quarter to $14.8B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2021, filed 16 Aug 2021.